Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCC
Aiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
Source: onclive.com
Unresectable Hcc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Unresectable Hcc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Unresectable Hcc Today - Breaking & Trending Today
Efficacy and Safety Outcomes in Combination Immunotherapy for uHCC
An expert analysis in data surrounding treatment outcomes in combination regimens, noting immune-mediate adverse events and overall impact on treatment response.
Source: onclive.com
The Evolving Landscape of Hepatocellular Carcinoma
Anwaar Saeed, MD, and Amit Singal, MD, discuss the evolving treatment landscape for hepatocellular carcinoma, highlighting FDA approvals and the utility of clinical biomarkers.
Source: onclive.com
Atezolizumab plus Bevacizumab in the Treatment of Unresectable HCC
A comprehensive review of clinical data of atezolizumab plus bevacizumab for the treatment of unresectable HCC.
Source: onclive.com
Expansion of First-Line Treatment Options in Unresectable HCC Requires Consideration of High-Risk Disease Features
Reena J. Salgia, MD, discusses the advantages of utilizing an atezolizumab plus bevacizumab backbone as standard frontline therapy in unresectable HCC; how factors such as Child-Pugh B score, bleeding, and other high-risk features impact treatment selection; and the unmet needs that still need to be addressed for this patient population.
Source: onclive.com